These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 12502367

  • 1. New benzo[h][1,6]naphthyridine and azepino[3,2-c]quinoline derivatives as selective antagonists of 5-HT4 receptors: binding profile and pharmacological characterization.
    Hinschberger A, Butt S, Lelong V, Boulouard M, Dumuis A, Dauphin F, Bureau R, Pfeiffer B, Renard P, Rault S.
    J Med Chem; 2003 Jan 02; 46(1):138-47. PubMed ID: 12502367
    [Abstract] [Full Text] [Related]

  • 2. Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
    Lemaître S, Lepailleur A, Bureau R, Butt-Gueulle S, Lelong-Boulouard V, Duchatelle P, Boulouard M, Dumuis A, Daveu C, Lezoualc'h F, Pfeiffer B, Dauphin F, Rault S.
    Bioorg Med Chem; 2009 Mar 15; 17(6):2607-22. PubMed ID: 19261477
    [Abstract] [Full Text] [Related]

  • 3. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
    Tapia I, Alonso-Cires L, López-Tudanca PL, Mosquera R, Labeaga L, Innerárity A, Orjales A.
    J Med Chem; 1999 Jul 29; 42(15):2870-80. PubMed ID: 10425096
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A, Alonso-Cires L, López-Tudanca PL, Tapia I, Labeaga L, Mosquera R.
    Drug Des Discov; 2000 Jul 29; 16(4):271-9. PubMed ID: 10807033
    [Abstract] [Full Text] [Related]

  • 5. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity.
    Pertz HH, Milhahn H, Eich E.
    J Med Chem; 1999 Feb 25; 42(4):659-68. PubMed ID: 10052973
    [Abstract] [Full Text] [Related]

  • 6. New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT4 receptors.
    Yang D, Soulier JL, Sicsic S, Mathé-Allainmat M, Brémont B, Croci T, Cardamone R, Aureggi G, Langlois M.
    J Med Chem; 1997 Feb 14; 40(4):608-21. PubMed ID: 9046352
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors.
    Berque-Bestel I, Soulier JL, Giner M, Rivail L, Langlois M, Sicsic S.
    J Med Chem; 2003 Jun 19; 46(13):2606-20. PubMed ID: 12801225
    [Abstract] [Full Text] [Related]

  • 8. Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents.
    Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, Perrone R, Tortorella V.
    J Med Chem; 2004 Dec 16; 47(26):6616-24. PubMed ID: 15588097
    [Abstract] [Full Text] [Related]

  • 9. Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists.
    Holmberg P, Sohn D, Leideborg R, Caldirola P, Zlatoidsky P, Hanson S, Mohell N, Rosqvist S, Nordvall G, Johansson AM, Johansson R.
    J Med Chem; 2004 Jul 29; 47(16):3927-30. PubMed ID: 15267230
    [Abstract] [Full Text] [Related]

  • 10. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.
    Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc'h F, Fischmeister R, Dumuis A, Bockaert J, George P, Soubrié P, Scatton B.
    J Pharmacol Exp Ther; 2002 Aug 29; 302(2):731-41. PubMed ID: 12130738
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y, Fujiwara I, Suzuki K, Harada H, Yoshikawa T, Yoshida N, Kato S.
    J Med Chem; 2003 Feb 27; 46(5):702-15. PubMed ID: 12593651
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
    Chambers JJ, Parrish JC, Jensen NH, Kurrasch-Orbaugh DM, Marona-Lewicka D, Nichols DE.
    J Med Chem; 2003 Jul 31; 46(16):3526-35. PubMed ID: 12877591
    [Abstract] [Full Text] [Related]

  • 15. Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists.
    Seong CM, Park WK, Park CM, Kong JY, Park NS.
    Bioorg Med Chem Lett; 2008 Jan 15; 18(2):738-43. PubMed ID: 18053713
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
    Schaus JM, Thompson DC, Bloomquist WE, Susemichel AD, Calligaro DO, Cohen ML.
    J Med Chem; 1998 May 21; 41(11):1943-55. PubMed ID: 9599243
    [Abstract] [Full Text] [Related]

  • 17. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.
    Medina RA, Sallander J, Benhamú B, Porras E, Campillo M, Pardo L, López-Rodríguez ML.
    J Med Chem; 2009 Apr 23; 52(8):2384-92. PubMed ID: 19326916
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine.
    Jorand-Lebrun C, Pauwels PJ, Palmier C, Moret C, Chopin P, Perez M, Marien M, Halazy S.
    J Med Chem; 1997 Nov 21; 40(24):3974-8. PubMed ID: 9397179
    [Abstract] [Full Text] [Related]

  • 20. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
    Cappelli A, Anzini M, Vomero S, Mennuni L, Makovec F, Doucet E, Hamon M, Bruni G, Romeo MR, Menziani MC, De Benedetti PG, Langer T.
    J Med Chem; 1998 Feb 26; 41(5):728-41. PubMed ID: 9513601
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.